中华内科杂志2023年6月第62卷第6期Chin J Intem Med,Jne2023.Val.62.No.6·631·标准与讨论·糖皮质激素性骨质疏松症的诊疗规范何菁·李芬2黄文辉3王丽萍4张学武·赵岩5代表中华医学会风湿病学分会·北京大学人民医院风湿免疫科，北京100044：2中南大学湘雅二医院风湿免疫科，长沙410011:3广州医科大学附属第二医院风湿免疫科，广州510260：4兰州大学第二医院风湿免疫科，兰州730030：5中国医学科学院北京协和医学院北京协和医院风湿免疫科国家皮肤与免疫疾病临床医学研究中心疑难重症和罕见病国家重点实验室风湿免疫病教育部重点实验室，北京100730通信作者：张学武，Email:xuewulore@l63.com;赵岩，Email:zhaoyan_pumch.2002@aliyun.com【摘要】糖皮质激素性骨质疏松症(GIOP)是长期使用糖皮质激素相关的以骨强度下降和骨折风险增高为特征的骨酪疾病，是最常见的继发性骨质疏松症，严重影响患者生活质量。目前我国G1OP发生率高，防治意识不足，防治规范欠缺。为此，中华医学会风湿病学分会在借鉴国内外诊治经验的基础上制定了本规范，旨在提高临床医师的防治意识，指导GOP的规范诊治，改善患者整体预后。【关键词】糖皮质激素类；骨质硫松：预防；治疗；规范Guidelines for diagnosis and treatment ofglucocorticoid-induced osteoporosisHe Jing',Li Fer,Huang Wenhur,Wang Liping,Zhang Xuewu',Zhao Yan,on behalf of ChineseRheumatology AssociationDepartment of Rheumatology and Immunology,Peking University People's Hospital,Beijing 100044,China;'Department of Rheumatology and Immunology,the Second Xiangya Hospital of Central SouthUniversity,Changsha 410011,China;Department of Rheumatology and Immunology,the SecondAffiliated Hospital of Guangzhou Medical University,Guangzhou 510260,China;Department ofRheumatology,Lanzhou University Second Hospital,Lanzhou 730030,China;sDepartment ofRheumatology and Clinical Immunology,Peking Union Medical College Hospital,Peking Union MedicalCollege,Chinese Academy of Medical Sciences,National Clinical Research Center for Dermatologic andImmunologic Diseases Ministry of Science &Technology,State Key Laboratory of Complex Severe andRare Diseases,Key Laboratory of Rheumatology and Clinical Immunology,Ministry of Education,Be时ing100730,ChinaCorresponding authors:Zhang Xuewu,Email:xuewulore@163.com;Zhao Yan,Email:zhaoyan_pumch2002@aliyun.comAbstract Glucocorticoid-induced osteoporosis(GIOP)is a skeletal disease characterizedby decreased bone strength and increased fracture risk associated with long-term glucocorticoiduse.GIOP is the most common secondary osteoporosis that critically affects the quality of life ofpatients.Currently,the incidence of GIOP in China remains high,with insufficient awareness and lackof prevention and treatment norms.Therefore,the Chinese Rheumatology Association hasestablished this standard based on domestic and international experience,with the aim of raisingawareness of prevention and treatment among clinicians,guiding the standardized diagnosis andtreatment of this disease,and improving the overall prognosis of patients with GIOP.D01:10.3760/cma.i.cnl12138-20221025-00787收稿日期2022-10-25本文编辑胡朝晖引用本文：何菁，李芬，黄文辉，等.糖皮质激素性骨质硫松症的诊疗规范中华内科杂志，2023,62(6631-638.D0:10.3760/cma-j.cm112138-20221025-00787.
